Voyager Therapeutics, Inc. Common Stock (VYGR) — 分析摘要
Voyager Therapeutics, Inc. Common Stock（VYGR）的市值为195.76百万美元，最近一年的营收同比增长了-49.5%。净利润率为-296.5%。当前市盈率为-1.7倍。
核心要点
- 营收同比变化-49.5%
- 净利润率-296.5%
- 市盈率-1.7倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，VYGR的营收增长为-49.5%，市盈率为-1.7倍。
Voyager Therapeutics, Inc. Common Stock (VYGR)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -349.2% — 严重经营亏损
净利率为 -319.6% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
141
总部
LEXINGTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。